Back to Search
Start Over
Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives
- Publication Year :
- 2019
-
Abstract
- Collecting ducts carcinoma (CDC) is a rare and aggressive histological subtype of renal cancer accounting for only 1% of renal tumors. Usually patients present in bad clinical conditions due to a symptomatic disease with synchronous metastasis. Due to the rarity of CDC, data from prospective trials evaluating the best treatment for these patients are limited. The prognosis is poor with a median overall survival of around 11 months for patients with metastatic disease. The best treatment option today is considered a doublet chemotherapy with platinum salt plus gemcitabine as a result from a prospective phase II trial, but survival outcomes remain unsatisfactory. The interest in the in-depth understanding the biology of this orphan disease is growing, leading to find potential new biological-driven treatment approaches. Here we review the up-to-date literature evidences to address the best management of this rare and unfavorable clinical condition.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
medicine.medical_treatment
Disease
03 medical and health sciences
0302 clinical medicine
Internal medicine
Carcinoma
Overall survival
Medicine
Animals
Humans
Radiology, Nuclear Medicine and imaging
Carcinoma, Renal Cell
Chemotherapy
business.industry
Treatment options
Cancer
Disease Management
General Medicine
medicine.disease
Prognosis
Combined Modality Therapy
Gemcitabine
Kidney Neoplasms
030104 developmental biology
Treatment Outcome
030220 oncology & carcinogenesis
Synchronous metastasis
business
medicine.drug
Subjects
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....05716feeef6e2706f5103499a3434875